Nerandomilast has 3 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Pirfenidone, Strong Or Moderate Cyp3a Inducers, Mao Inhibitors. Patients taking Nerandomilast should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Major
- 2
- Moderate
- 1
Major (2)
- Nerandomilast + Pirfenidone— Pirfenidone decreases exposure of nerandomilast and reduces efficacy at 9 mg twice daily dosage. Dosage should be mainta…
- Nerandomilast + Strong Or Moderate Cyp3a Inducers— Moderate or strong CYP3A inducers decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD. Concom…
Moderate (1)
- Nerandomilast + Mao Inhibitors— Strong CYP3A inhibitors increase exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions. Do…